Transforming MIBC Treatment: Insights from the NIAGARA TrialPosted on February 16, 2025The landscape of treating muscle-invasive bladder cancer (MIBC) has…
On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy…
